Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif.--(BUSINESS WIRE)-- #AI--Docbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEO

Docbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEO

LOS ANGELES, May  22, 2020  (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction with Qualigen, Inc. is currently expected to close after market hours today, Friday, May 22, 2020.

Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.

LOS ANGELES, May  19, 2020  (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote count certified by the inspector of election for the special meeting of stockholders held on May 18, 2020, its stockholders approved all of the Qualigen, Inc. merger-related proposals, including: (i) the issuance of Ritter common stock and convertible preferred stock pursuant to the Agreement and Plan of Merger, dated as of January 15, 2020, as amended, by and among Ritter, RPG28 Merger Sub, Inc., and Qualigen, Inc. (“Qualigen”) and the change of control of Ritter resulting from the merger, (ii) a reverse stock split of the outstanding shares of common stock of the Company, at a ratio within a range of 1-for-25 to 1-for-35, as determined by the board of directors of the Company, (iii) changing the name of Ritter from “Ritter Pharmaceuticals, Inc.” to “Qualigen Therapeutics, Inc.” and (iv) the adoption of Ritter’s 2020 Equity Incentive Plan.

Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.

LOS ANGELES, May  14, 2020  (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter” or the “Company”), today announced that it has adjourned its special meeting of stockholders, originally scheduled for today, until Monday, May 18, 2020 at 12:00 p.m., Pacific Time. The special meeting was adjourned to allow the Company additional time to solicit proxies in favor of the proposals to be acted on by stockholders at the meeting.

Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting

LOS ANGELES, May  11, 2020  (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing

LOS ANGELES, May  06, 2020  (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional investors with voting assessment and recommendations based on evaluating governance, business, legal, political and accounting risks at public companies, have recommended that Ritter Pharmaceuticals stockholders vote “FOR” the Company’s proposed merger with Qualigen, Inc. (“Qualigen”) and each of the merger proposals to be considered at Ritter Pharmaceuticals’ upcoming special meeting of stockholders scheduled for May 14, 2020.

Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals

LOS ANGELES, May  01, 2020  (GLOBE NEWSWIRE) -- Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway

Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020

The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split.

Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.

Special Meeting of Ritter Pharmaceuticals, Inc. Stockholders  to Vote on Proposed Merger Scheduled for May 14, 2020

Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC

Definitive merger agreement with Qualigen, Inc. announced in January 2020

Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019

Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs

Ritter Pharmaceuticals, Inc. and Qualigen, Inc.

LOS ANGELES, Nov.  13, 2019  (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today reported recent business developments and financial results for the three and nine months ended September 30, 2019.

Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update

Shares of thinly-trade Ritter Pharmaceuticals Inc (NASDAQ: RTTR) are plunging to an all-time low Friday morning following a clinical readout.

Investors Push Ritter Pharma Shares To Record Low Over Failed Lactose Intolerance Drug Trial

LOS ANGELES, Sept.  12, 2019  (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, announced today that its Phase 3 clinical trial of RP-G28 for lactose intolerance (LI) failed to demonstrate statistical significance in its pre-specified primary endpoint.

Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

News for Ritter Pharmaceuticals Stock (RTTR)